Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Moderate Buy” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $38.57.

Several analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Wedbush raised their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th.

Insider Activity

In related news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $11.44, for a total transaction of $29,435.12. Following the completion of the transaction, the chief financial officer now owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently made changes to their positions in ZNTL. Wealth Enhancement Advisory Services LLC acquired a new stake in Zentalis Pharmaceuticals in the 1st quarter valued at about $680,000. Los Angeles Capital Management LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 1st quarter worth approximately $606,000. Eventide Asset Management LLC grew its position in shares of Zentalis Pharmaceuticals by 47.9% in the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after purchasing an additional 3,745,936 shares in the last quarter. Birchview Capital LP acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $242,000. Finally, Pennant Investors LP purchased a new position in Zentalis Pharmaceuticals during the fourth quarter worth approximately $491,000.

Zentalis Pharmaceuticals Stock Down 6.4 %

Shares of ZNTL stock opened at $11.77 on Thursday. The stock has a market cap of $835.20 million, a PE ratio of -2.59 and a beta of 1.73. Zentalis Pharmaceuticals has a 52-week low of $9.56 and a 52-week high of $31.46. The business has a 50-day simple moving average of $14.15 and a 200-day simple moving average of $13.93.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.09. Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.